Monday, November 9, 2026
Adjuvia Therapeutics Initiates Phase 1 Clinical Trial of ATI-105 for Friedreich’s Ataxia
Oct 28, 2026. SAN FRANCISCO--(BUSINESS WIRE)--Adjuvia Therapeutics, a biotechnology company developing novel therapeutics to treat mitochondrial dysfunction and disease, today announced that the first participant has been dosed in its Phase 1 clinical trial of ATI-105, its lead investigational therapeutic candidate for Friedreich’s ataxia (FA). The milestone follows the U.S. Food and Drug Administration's (FDA) acceptance of the company's Investigational New Drug (IND) application in September.Adjuvia plans to advance ATI-105 into Phase 1/2 studies in FA in 2027, with a focus on addressing lethal cardiomyopathy, followed by expansions into Leigh syndrome and primary mitochondrial diseases (PMD) in 2028.
